Home › Acute Biphenotypic Leukemia
Pag-aaral pangklinika para sa Acute Biphenotypic Leukemia na nagre-recruit sa U.S.
38 pag-aaral para sa Acute Biphenotypic Leukemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Seattle, WA15 pag-aaral
- Houston, TX11 pag-aaral
- New York City, NY10 pag-aaral
- Atlanta, GA9 pag-aaral
- Durham, NC8 pag-aaral
- Chicago, IL7 pag-aaral
- Memphis, TN7 pag-aaral
- Portland, OR6 pag-aaral
- Philadelphia, PA6 pag-aaral
- Aurora, CO6 pag-aaral
- Los Angeles, CA6 pag-aaral
- Charlotte, NC6 pag-aaral
- Dallas, TX6 pag-aaral
- Baldwin Park, CA6 pag-aaral
- Columbus, OH5 pag-aaral
- Tampa, FL5 pag-aaral
- Nashville, TN5 pag-aaral
- Clifton, NJ5 pag-aaral
- Boston, MA5 pag-aaral
- Fort Worth, TX5 pag-aaral
- Minneapolis, MN5 pag-aaral
- San Francisco, CA5 pag-aaral
- Greenburgh, NY5 pag-aaral
- Cincinnati, OH5 pag-aaral
- San Diego, CA5 pag-aaral
- St. Louis, MO4 pag-aaral
- Gainesville, FL4 pag-aaral
- Greenville, NC4 pag-aaral
- Orange, CA4 pag-aaral
- Indianapolis, IN4 pag-aaral
- Ann Arbor, MI4 pag-aaral
- Jacksonville, FL4 pag-aaral
- Washington, DC4 pag-aaral
- Cleveland, OH4 pag-aaral
- Milwaukee, WI4 pag-aaral
- Queens, NY4 pag-aaral
- Louisville, KY4 pag-aaral
- Omaha, NE4 pag-aaral
- Edison, NJ4 pag-aaral
- Miami, FL4 pag-aaral
Ayos sa estado
- Alabama3 pag-aaral
- Alaska3 pag-aaral
- Arizona4 pag-aaral
- Arkansas3 pag-aaral
- California15 pag-aaral
- Colorado8 pag-aaral
- Connecticut3 pag-aaral
- Delaware3 pag-aaral
- District of Columbia4 pag-aaral
- Florida9 pag-aaral
- Georgia9 pag-aaral
- Hawaii3 pag-aaral
- Idaho3 pag-aaral
- Illinois7 pag-aaral
- Indiana4 pag-aaral
- Iowa4 pag-aaral
- Kentucky4 pag-aaral
- Louisiana4 pag-aaral
- Maine3 pag-aaral
- Maryland4 pag-aaral
- Massachusetts5 pag-aaral
- Michigan4 pag-aaral
- Minnesota6 pag-aaral
- Mississippi3 pag-aaral
- Missouri5 pag-aaral
- Nebraska4 pag-aaral
- Nevada3 pag-aaral
- New Hampshire3 pag-aaral
- New Jersey6 pag-aaral
- New York11 pag-aaral
- North Carolina11 pag-aaral
- North Dakota3 pag-aaral
- Ohio8 pag-aaral
- Oklahoma5 pag-aaral
- Oregon6 pag-aaral
- Pennsylvania6 pag-aaral
- Rhode Island3 pag-aaral
- South Carolina3 pag-aaral
- South Dakota3 pag-aaral
- Tennessee10 pag-aaral
- Texas13 pag-aaral
- Utah3 pag-aaral
- Virginia3 pag-aaral
- Washington15 pag-aaral
- West Virginia3 pag-aaral
- Wisconsin5 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT02115295Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT04797767Personalized NK Cell Therapy in CBT
Nagre-recruitPhase 2
Edad 15 hanggang 80 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT02727803Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Hanggang edad 50 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT05322850Prophylactic DLI-X for Leukemia Relapse After HCT
Nagre-recruitPhase 1
Hanggang edad 65 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT07254793Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT01137643Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Nagre-recruitPhase 2
365 Days · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT06317662Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Nagre-recruitPhase 2
6 Months – 65 Years · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06013423Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Okt 22, 2026 · NCT06177067A Study of Revumenib and Mezigdomide in People With Leukemia
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Okt 20, 2026 · NCT07356154Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT07094750Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Nagre-recruitPhase 1
Edad 2 pataas · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT06575296A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Okt 9, 2026 · NCT04065399A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Nagre-recruitPhase 1
Edad 12 hanggang 78 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT03802695CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04375631Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT03683433Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Nagre-recruitPhase 3
365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Nagre-recruitPhase 2
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06390319Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Nagre-recruitPhase 4
Edad 1 hanggang 18 · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
Nagre-recruitPhase 2
Hanggang edad 75 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT05805605Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.